Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „zanubrutinib“
Suchtreffer
Begriffe & Kennungen
Brukinsa · 4.5 · Agents that may decrease zanubrutinib plasma concentrations
Eintrag öffnenBrukinsa · 4.5 · Agents that may decrease zanubrutinib plasma concentrations
Eintrag öffnenBrukinsa · 4.5 · Agents that may have their plasma concentrations altered by zanubrutinib
Eintrag öffnenBrukinsa · 4.5 · Agents that may have their plasma concentrations altered by zanubrutinib
Eintrag öffnenBrukinsa · 4.5 · Agents that may increase zanubrutinib plasma concentrations
Eintrag öffnenBrukinsa · 4.5 · Agents that may increase zanubrutinib plasma concentrations
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of rifampicin (strong CYP3A inducer) decreased zanubrutinib Cmax by 92% an
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of rifampicin (strong CYP3A inducer) decreased zanubrutinib Cmax by 92% an
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib decreased midazolam (CYP3A substrate) Cmax by 30% and AUC
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib decreased midazolam (CYP3A substrate) Cmax by 30% and AUC
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib decreased omeprazole (CYP2C19 substrate) Cmax by 20% and A
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib decreased omeprazole (CYP2C19 substrate) Cmax by 20% and A
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib increased digoxin (P-gp substrate) Cmax by 34% and AUC by
Eintrag öffnenBrukinsa · 4.5 · Co-administration of multiple doses of zanubrutinib increased digoxin (P-gp substrate) Cmax by 34% and AUC by
Eintrag öffnenBrukinsa · 4.5 · Concomitant use of zanubrutinib and strong or moderate inducers of CYP3A can decrease zanubrutinib plasma conc
Eintrag öffnenBrukinsa · 4.5 · Concomitant use of zanubrutinib and strong or moderate inducers of CYP3A can decrease zanubrutinib plasma conc
Eintrag öffnenBrukinsa · 4.5 · No clinically significant differences in zanubrutinib pharmacokinetics were observed when co-administered with
Eintrag öffnenBrukinsa · 4.5 · No clinically significant differences in zanubrutinib pharmacokinetics were observed when co-administered with
Eintrag öffnenBrukinsa · 4.5 · Zanubrutinib is a mild inducer of CYP3A and CYP2C19. Concomitant use of zanubrutinib can decrease the plasma c
Eintrag öffnenBrukinsa · 4.5 · Zanubrutinib is a mild inducer of CYP3A and CYP2C19. Concomitant use of zanubrutinib can decrease the plasma c
Eintrag öffnen